Adamantiades-Behçet's disease therapy: current treatment options and recommendations with regard to the COVID-19 pandemic.
Dermatol Ther
; 35(3): e15286, 2022 Mar.
Article
in English
| MEDLINE | ID: covidwho-1638477
ABSTRACT
Adamantiades-Behçet's disease (ABD) is a chronic, idiopathic, relapsing immune-mediate disease that may involve multiple organs. It is characterized by recurrent oral and genital ulcers, skin lesions, ocular, gastrointestinal, vascular, neurological and joint involvement. It can lead to significant morbidity and mortality. Due to its heterogeneity in clinical findings and physiopathology, its treatment can be various as ABD manifestations in different organs may differently respond to the same drug. The cornerstone of therapy for inducing remission is systemic corticosteroid, whereas immunomodulatory and immunosuppressive agents such as colchicine, azathioprine, cyclosporine-A, interferon-alpha, and cyclophosphamide are used as steroid-sparing agents and to prevent relapses. For aggressive, refractory or frequently relapsing cases, tumor necrosis factor (TNF) alpha inhibitors (infliximab, adalimumab, etanercept) have been reported beneficial. Herein, we describe our experience of 7 patients treated with TNF-alpha inhibitors with recommendations regarding treatment choice during the COVID-19 era.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Behcet Syndrome
/
COVID-19 Drug Treatment
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Dermatol Ther
Journal subject:
Dermatology
Year:
2022
Document Type:
Article
Affiliation country:
Dth.15286
Similar
MEDLINE
...
LILACS
LIS